The Pujiang Innovation Forum 2026 Brain-Computer Interface Conference will bring researchers, clinicians, technology companies, manufacturers and investors to Shanghai from December 3–6, 2026, creating a focused platform for exploring China’s rapidly developing brain-computer interface industry.
Held under the theme “Connecting Brains Worldwide, Converging Intelligence in Shanghai,” the programme will combine an investment forum, developer conference, technology competitions, product launches, specialist forums, supply-chain meetings and an exhibition.
Activities will take place across the Shanghai Hongqiao Conference Center and Naozhi Tiandi, also known as Shanghai Brain Intelligence World, a specialised brain-computer interface industry cluster in Minhang District.
Shanghai BCI Conference 2026 at a Glance
| Event information | Details |
|---|---|
| Event | Pujiang Innovation Forum 2026 Brain-Computer Interface Conference |
| Full programme | December 3–6, 2026 |
| Investment forum | December 4 |
| Main conference and exhibition | December 5–6 |
| Locations | Shanghai Hongqiao Conference Center and Naozhi Tiandi |
| Theme | Connecting Brains Worldwide, Converging Intelligence in Shanghai |
| Expected exhibitors | More than 100; organiser publicity forecasts 150–200 |
| Planned exhibition area | Up to 20,000 square metres, according to the organiser |
| Visitor admission | Free for approved, pre-registered participants |
| Visitor application deadline | November 25, 2026 |
| Standard booth price | RMB 18,800 for nine square metres |
International visitors can submit an application through the official conference registration page. The Shanghai government’s official conference notice states that applications are subject to review and successful applicants will receive a participation notice.
Businesses comparing other technology and healthcare events can also use the China trade show calendar.
Dates Clarified: December 3–6, Not Only December 4–6
The English-language press release describes the conference as running from December 4–6. However, the Shanghai Municipal Government lists the complete programme as December 3–6.
The difference appears to reflect the structure of the event:
- December 3: Opening or supporting programme activities
- December 4: Investment and financing forum at Naozhi Tiandi
- December 5–6: Main conference, exhibition and related activities at Shanghai Hongqiao Conference Center
Visitors should check their approved invitation and the final programme before booking transport between the two venues.
Exhibition to Cover the BCI Value Chain
The conference includes a dedicated supply-chain exhibition covering technologies required to develop, manufacture, test and commercialise brain-computer interface systems.
Expected product and service areas include:
- Neural signal acquisition equipment
- Electrodes and electrode materials
- Neural and signal-processing chips
- Sensors and electronic components
- Brain-signal decoding algorithms
- AI and machine-learning platforms
- BCI software and development tools
- Precision manufacturing services
- Testing and certification
- Medical-device registration services
- Clinical research and validation
- Rehabilitation equipment
- Neurostimulation systems
- Consumer and wellness applications
- Data, computing and cloud infrastructure
The organiser’s press release forecasts a 20,000-square-metre exhibition with 150–200 exhibitors. Reporting from the Shanghai conference briefing more conservatively states that more than 100 companies are expected to participate.
Until a final exhibitor directory is published, both figures should be treated as forecasts.
Confirmed Companies Include BrainCo, Neuracle and StairMed
The organiser has named several Chinese brain-computer interface companies expected to participate, including:
- StairMed
- Neuracle
- Active Intelligence Technologies
- BrainCo
The event is intended to place component suppliers, device developers, clinical institutions, manufacturers and service providers in direct contact.
This supply-chain emphasis distinguishes the conference from a purely academic neuroscience event. For commercial participants, the most relevant discussions are likely to concern manufacturability, clinical evidence, regulatory approval, supplier qualification and access to application scenarios.
Shanghai Is Building a Concentrated BCI Industry Cluster
According to the Shanghai Municipal Government, the city now has more than 120 brain-computer interface companies, with Minhang District accounting for a large share of the cluster.
Shanghai reports that BCI companies in the city raised more than RMB 4 billion during 2026, while three companies began preparations for initial public offerings.
Naozhi Tiandi is at the centre of this development. The cluster combines companies with clinical, research, regulatory and investment resources, including:
- A brain-computer interface proof-of-concept platform
- The Sinan BCI Super Incubator
- Clinical translation facilities
- Research wards
- Brain-signal datasets
- Testing and regulatory services
- Computing and data infrastructure
- Investment and professional-service organisations
Shanghai says the Sinan incubator currently accommodates 26 companies, while the wider Minhang ecosystem covers electrodes, chips, algorithms, rehabilitation terminals, clinical research services and medical-device testing.
These figures come from local government reporting and should be understood as official development indicators rather than independently audited market statistics.
Investment Forum Targets BCI Companies and Specialist Capital
The Brain-Computer Interface Investment and Financing Forum will take place on December 4 at Naozhi Tiandi.
According to the forum programme published by Frost & Sullivan, it will bring together:
- Venture-capital firms
- Private-equity investors
- Government guidance funds
- Corporate investment teams
- Listed companies
- Family offices
- BCI startups
- Clinical and research experts
- Capital-market service providers
The forum is expected to examine technical valuation, clinical evidence, medical-device registration, financing strategies and routes to commercialisation.
Frost & Sullivan says the programme aims to attract approximately 150 investment institutions and 50 innovation projects. Project pitches and investor matching are planned alongside industry analysis and panel discussions.
For investors, the event may help distinguish BCI projects that have a credible clinical, regulatory and manufacturing pathway from those still centred mainly on research demonstrations.
Clinical Translation Takes Priority
Brain-computer interfaces include both medical and non-medical applications, but much of the Shanghai programme focuses on clinical translation.
Potential medical applications include:
- Restoring movement after spinal-cord injury
- Stroke rehabilitation
- Epilepsy assessment and treatment
- Neurostimulation
- Speech and communication assistance
- Mental-health interventions
- Sleep-disorder treatment
- Cognitive assessment
- Assistive control systems
International companies evaluating Chinese BCI products should determine whether a displayed system is:
- A research prototype
- An engineering sample
- Entering clinical trials
- Undergoing medical-device registration
- Approved for commercial clinical use
- Intended only for research, wellness or consumer applications
A visually impressive demonstration does not by itself establish clinical effectiveness, safety or regulatory approval.
ChinaExpoHub’s earlier coverage of CMEF Beijing 2026 discusses similar questions for buyers assessing brain-computer interfaces, medical AI and rehabilitation technology.
New National BCI Data Platform to Be Introduced
The Shanghai government says the conference will include the launch of preparations for a national brain-computer interface data centre.
The programme is also expected to introduce U-RUN 1.1, a data infrastructure designed to connect brain-signal data, algorithms and clinical applications.
Data infrastructure is commercially important because BCI development depends on access to sufficiently large, well-governed datasets. Companies should assess:
- How patient consent is obtained
- Whether data is identifiable or anonymised
- Who controls access to datasets
- Whether data can leave China
- How algorithms are validated
- Which hospitals and research institutions contribute data
- How intellectual-property rights are allocated
- Which cybersecurity and medical-data rules apply
International companies should not assume that data generated in China can be freely transferred to overseas research or cloud environments.
Developer Conference and Technology Competitions
The wider conference follows a “1+6+N” structure comprising one principal forum, six central programme areas and additional supporting activities.
The six main elements include:
- International developer conference
- Brain-computer interface competitions
- Investment and financing forum
- Supply-chain conference
- New-product launches
- Frontier-technology forums
The competitions will examine algorithm performance, system engineering and product development. According to the official Shanghai announcement, challenges will include invasive BCI algorithms and engineering implementation.
For startups and researchers, these competitions may provide access to clinical requirements, development tools, technical partners and potential investors.
What International Buyers and Partners Should Assess
The conference will be most relevant to:
- BCI device developers
- Medical-device manufacturers
- Rehabilitation equipment companies
- Hospitals and clinical research organisations
- Chip and sensor companies
- Electrode and advanced-material suppliers
- AI and signal-processing developers
- Precision manufacturers
- Testing and certification providers
- Investors and corporate venture teams
- Universities and neuroscience institutes
- Regulatory and market-entry specialists
Before entering a partnership, international participants should examine:
- Regulatory status
- Clinical evidence
- Patient population and intended use
- Hardware and software ownership
- Patent position
- Manufacturing readiness
- Component dependencies
- Data governance
- Cybersecurity
- Export controls
- Distribution and after-sales responsibilities
- Reimbursement and payment pathways
BCI remains a technically complex and regulated field. Companies should distinguish between early research cooperation, clinical development, component sourcing and commercial distribution.
Visitor Registration and Exhibition Costs
Visitor participation is free, but registration and organiser approval are required.
The Shanghai government asks applicants to register by November 25, 2026. Visitors can apply through the conference registration system.
The organiser lists a standard nine-square-metre booth at RMB 18,800. Companies interested in exhibiting, launching products or seeking partnerships can contact the organising team at [email protected].
Because the event uses two locations and different programme dates, participants should confirm:
- Which sessions their registration covers
- The venue for each activity
- Whether interpretation is available
- Whether advance appointments are required
- Whether access is limited to approved professionals
- The final exhibition opening hours
Why the Conference Matters
The Pujiang Innovation Forum 2026 Brain-Computer Interface Conference brings together several elements that are often separated at technology events: research, clinical validation, manufacturing, regulation, investment and supply-chain development.
For international companies, its value lies less in conventional product sourcing and more in understanding how China’s BCI industry is moving from laboratory research towards regulated medical products and scalable manufacturing.
The strongest opportunities may be found in:
- Specialist components and materials
- Clinical and regulatory services
- Manufacturing partnerships
- Medical-device testing
- AI and signal processing
- Rehabilitation applications
- International research cooperation
- Investment and technology licensing
The conference offers a useful entry point into Shanghai’s expanding neurotechnology ecosystem, but potential partners and products will still require detailed technical, clinical and commercial due diligence.